Risk management of renal biopsy: 1387 cases over 30 years in a single centre

Background Although renal biopsy is largely employed, even in old patients with systemic diseases, few clinical studies have addressed its risk management. We aimed to obtain a comprehensive assessment of safety/utility ratio of percutaneous renal biopsy. Patients and methods Retrospective review of all the 1387 patients who consecutively underwent renal biopsy in a single centre over three decades (1973–2002) was made, with calculation of complications, multivariate logistical analyses to evaluate risk factors of complications, and rate of alteration of clinical hypotheses by pathological diagnosis. Results There were no deaths and five major complications, (0·36%). One nephrectomy (0·07%), two surgical revisions (0·1%) and two arterial-venous fistulae (0·1%). There were also 337 minor bleeding complications (24·2%) (16·4% gross haematuria and 7·8% clinically relevant haematomas needing at least prolonged bed rest). Multivariate analyses demonstrated that the risk for complications was significantly increased by systemic autoimmune diseases with odds ratio (OR) 2·06, 95% confidence interval (CI) = 1·40–3·01, end-stage kidney/acute-tubular necrosis (OR 2·96, 95% CI = 1·19–7·30), and prolonged bleeding time test (BTT) (OR 1·87, 95% CI = 1·17–2·83). Among the 1288 cases in which a clinical hypothesis before renal biopsy was recorded, renal pathology changed previous diagnoses in 423/1,288 (32·8%) of cases. Conclusions Risk assessment demonstrates that renal biopsy is a useful procedure with a low incidence of serious complications. Platelet function is the only modifiable factor significantly related to bleeding complications, suggesting the need for a more standardized alternative to the BTT. Platelet function should be evaluated to select low-risk patients for renal biopsy as ‘a day case procedure’, in order to build adequate risk management strategies.